In vitro induction of specific CD8(+) T lymphocytes by tumorassociated antigenic peptides in patients with oral squamous cell carcinoma
In vitro induction of specific CD8(+) T lymphocytes by tumorassociated antigenic peptides in patients with oral squamous cell carcinoma
复制标题
肿瘤相关抗原肽体外诱导口腔鳞状细胞癌患者特异性CD8( ) T淋巴细胞
DOI：
10.1016/j.canlet.2012.02.016
复制
发表时间：
2012
期刊：
影响因子：
9.7
通讯作者：
S.
中科院分区：
文献类型：
--
作者：
Toyoshima;T.;Kumamaru;W.;Hayashida;J.-N.;Moriyama;M.;Kitamura;R.;Tanaka;H.;Yamada;A.;Itoh;K.;and Nakamura;S.
本研究的目的是阐明口腔鳞状细胞癌(SCC)多肽特异性免疫治疗的候选多肽。检测了35例口腔鳞癌患者外周血中13种多肽对CD8+T淋巴细胞(CD8+TL)的体外诱导活性。应用免疫组织化学方法对23例患者进行了CD8+TL诱导能力与宿主体内免疫应答的相关性研究。在35例患者中，有21例(60.0%)检测到至少一种多肽的CD8+TL多肽特异性活性。其中9/35为SART-1690(25.7%)，7/35为SART-293和ART475(20.0%)。在9例具有SART-1690特异性活性的患者中，与26例没有活性的患者相比，更多的其他多肽可以显著诱导整个活性(P=0.035)。有SART1690特异性活性的7例患者的细胞反应明显强于无该活性的16例患者(P=0.027)。此外，鳞癌周围CD3+T细胞的数量在两组患者之间也有显著差异(P=0.041)。综上所述，SART-1690、SART-293和ART475可用于大多数口腔鳞癌患者的多肽特异性免疫治疗。
The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined for in vitro induction of peptide-specific CD8+T lymphocyte (CD8+TL) activity in peripheral blood mononuclear cells from 35 patients with oral SCC. A correlation between the induction ability of CD8+TL and in vivo immune response of host was carried out immunohistochemically in 23 patients. Peptide-specific activities of CD8+TL for at least one peptide were detectable in 21/35 patients (60.0%). The potent peptides were SART-1690in 9/35 (25.7%), SART-293, and ART475in 7/35 (20.0%), respectively. In the 9 patients with SART-1690-specific activity, the whole of activities was significantly inducible for more number of other peptides compared to that in 26 patients without the activity (P=0.035). Cellular responses in 7 patients with SART-1690-specific activity were significantly stronger than those in 16 patients without the activity (P=0.027). Furthermore, the number of CD3+T cells around the SCC was also significantly different between the 2 groups of patients (P=0.041). In conclusion, SART-1690, SART-293, and ART475could be applicable as peptide-based specific immunotherapies for the majority of patients with oral SCC.